Chilblains outbreak during COVID-19 pandemic: A Type-I interferonopathy?

Pediatr Allergy Immunol. 2022 Oct;33(10):e13860. doi: 10.1111/pai.13860.

Anna Mensa-Vilaró^{1

2}, Asunción Vicente³, Marta Español-Rego¹, Jordi Antón^{4

5

6}, Virginia Fabregat¹, Claudia Fortuny⁷, Europa Azucena González¹, Victoria Fumadó⁷, Eva González-Roca¹, Cristina Jou^{6

8}, Susana Plaza¹, Juan Manuel Mosquera⁴, Jordi Yagüe^{1

2

5}, Carolina Prat³, Mariona Pascal^{1

2}, Manel Juan^{1

2

5}, Juan I Arostegui^{1

2

5}, Eulalia Baselga³, Laia Alsina^{5

6

9

10}

¹ Department of Immunology, Hospital Clínic, Barcelona, Spain.
² Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
³ Department of Dermatology, Hospital Sant Joan de Déu, Esplugues, Spain.
⁴ Department of Rheumatology, Hospital Sant Joan de Déu, Esplugues, Spain.
⁵ School of Medicine, Universitat de Barcelona, Barcelona, Spain.
⁶ Study Group for Immune Dysfunction Diseases in Children (GEMDIP), Institut de Recerca Hospital Sant Joan de Déu, Barcelona, Spain.
⁷ Department of Pediatrics, Infectious Disease Unit, Hospital Sant Joan de Déu, Esplugues, Spain.
⁸ Pathology Department and Biobank, Hospital Sant Joan de Déu, Esplugues, Spain.
⁹ Department of Allergy and Clinical Immunology, Clinical Immunology and Primary Immunodeficiencies Unit, Hospital Sant Joan de Déu, Esplugues, Spain.
¹⁰ Clinical Immunology Unit, Hospital Sant Joan de Déu-Hospital Clínic, Barcelona, Spain.

No abstract available

Publication types